Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM

Conference Correspondent  - ASH Highlights

The objective of the APOLLO study was to evaluate daratumumab (DARA; subcutaneous) + pomalidomide and dexamethasone (Pd) versus Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior lines of therapy, including lenalidomide (Len) and a proteasome inhibitor (PI). The data reported here are from the primary analysis.

Patients with RRMM who had received ≥1 prior lines of therapy, including Len and a PI (patients with only 1 prior line of therapy were required to be refractory to Len), and had responded to prior treatment and progressed on or after their last regimen, were eligible for this open-label study. Patients could not have previously taken anti-CD38 or Pd. Patients were randomized 1:1, and stratification was based on the International Staging System (ISS) disease stage and number of prior lines of therapy.

Treatment cycles were 28 days. Patients received pomalidomide (P) 4 mg once daily on days 1 to 21 and dexamethasone (d) 40 mg on days 1, 8, 15, and 22. For patients in the DARA-Pd arm, DARA was given once weekly for cycles 1 and 2, once every 2 weeks for cycles 3 to 6, and once every 4 weeks thereafter. Initially, patients received DARA intravenously (16 mg/kg; n = 7) but after protocol amendment, they received DARA subcutaneously 1800 mg co-formulated with recombinant human hyaluronidase PH20 (Halozyme, Inc). Treatment continued until disease progression (DP) or unacceptable toxicity. Progression-free survival (PFS) was the primary end point; secondary end points included overall response rate, rates of very good partial response or better (≥VGPR) and complete response or better (≥CR), minimal residual disease negativity rate, overall survival, and safety.

In APOLLO, 304 patients were randomized 1:1 to DARA-Pd (n = 151) or Pd alone (n = 153). The median age was 67 years (range, 35-90 years). ISS stage distribution was 45% stage I, 33% stage II, and 22% stage III. The presence of del17p, t(14;16), or t(4;14) was identified in 35% of patients, classifying them as high cytogenetic risk; 11% of patients had received 1 prior line of therapy (median, 2; range, 1-5). A total of 79.6% of patients were refractory to Len, 48.0% of patients were refractory to a PI, and 42.4% of patients were refractory to both. Median duration of treatment was 11.5 months (DARA-Pd) versus 6.6 months (Pd).

At primary analysis, a 37% reduction in the risk for progression or death in patients in the DARA-Pd arm was observed, meaning the study met the primary end point of improved PFS (hazard ratio, 0.63; 95% confidence interval, 0.47-0.85; P = .0018). Median PFS was 12.4 months versus 6.9 months for the DARA-Pd and Pd arms, respectively. At a median follow-up of 16.9 months, 99 patients (33%) have died; survival data are immature. In the DARA-Pd arm, 24.5% of patients achieved ≥CR and 51.0% achieved ≥VGPR, whereas in the Pd arm, 3.9% of patients achieved ≥CR and 19.6% achieved ≥VGPR. The minimal residual disease–negativity rate for the DARA-Pd arm was 9% versus 2% for the Pd arm. Benefits were seen across all prespecified subgroups.

The most common grade 3/4 adverse events (AEs), with a ≥5% difference between arms (DARA-Pd vs Pd), were neutropenia (68% vs 51%), leukopenia (17% vs 5%), lymphopenia (12% vs 3%), febrile neutropenia (9% vs 3%), and pneumonia (13% vs 7%). For DARA given subcutaneously, the rate of injection-related reactions was low (5%) and all were grade 1/2. Grade 1 local injection-site reactions occurred in 2% of patients. Discontinuations because of treatment-emergent AEs were similar between arms (2% DARA-Pd vs 3% Pd).

When compared with Pd, DARA-Pd significantly reduced the risk for DP or death by 37% for this patient population. No new safety signals were observed. The low rate of injection-related reactions and the short administration time (median, 5 minutes) associated with subcutaneous delivery of DARA decrease patient burden, making DARA-Pd an effective and convenient therapy for patients with RRMM who received ≥1 prior lines of therapy, including Len and a PI.


Reference

Abstract 412. ASH 2020. December 4, 2020. APOLLO: Phase 3 Randomized Study of Subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).

Related Items
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.